JP2018502922A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502922A5 JP2018502922A5 JP2017555422A JP2017555422A JP2018502922A5 JP 2018502922 A5 JP2018502922 A5 JP 2018502922A5 JP 2017555422 A JP2017555422 A JP 2017555422A JP 2017555422 A JP2017555422 A JP 2017555422A JP 2018502922 A5 JP2018502922 A5 JP 2018502922A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- ebola virus
- vector
- virus antigen
- adenovirus type
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 claims 21
- 241001115402 Ebolavirus Species 0.000 claims 16
- 239000000427 antigen Substances 0.000 claims 16
- 102000036639 antigens Human genes 0.000 claims 16
- 108091007433 antigens Proteins 0.000 claims 16
- 241001135569 Human adenovirus 5 Species 0.000 claims 10
- 108090000288 Glycoproteins Proteins 0.000 claims 8
- 102000003886 Glycoproteins Human genes 0.000 claims 8
- 150000007523 nucleic acids Chemical group 0.000 claims 6
- 102100021592 Interleukin-7 Human genes 0.000 claims 5
- 108010002586 Interleukin-7 Proteins 0.000 claims 5
- 230000002163 immunogen Effects 0.000 claims 5
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 4
- 230000028993 immune response Effects 0.000 claims 4
- 230000002950 deficient Effects 0.000 claims 3
- 238000012217 deletion Methods 0.000 claims 3
- 230000037430 deletion Effects 0.000 claims 3
- 230000008088 immune pathway Effects 0.000 claims 3
- 230000010076 replication Effects 0.000 claims 3
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims 2
- 241000884921 Bundibugyo ebolavirus Species 0.000 claims 2
- 102100038078 CD276 antigen Human genes 0.000 claims 2
- -1 CD86 Proteins 0.000 claims 2
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims 2
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims 2
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims 2
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 claims 2
- 101000652359 Homo sapiens Spermatogenesis-associated protein 2 Proteins 0.000 claims 2
- 102100037850 Interferon gamma Human genes 0.000 claims 2
- 108010074328 Interferon-gamma Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000017578 LAG3 Human genes 0.000 claims 2
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims 2
- 241001115394 Reston ebolavirus Species 0.000 claims 2
- 241001115376 Sudan ebolavirus Species 0.000 claims 2
- 230000024932 T cell mediated immunity Effects 0.000 claims 2
- 241001115374 Tai Forest ebolavirus Species 0.000 claims 2
- 102100038929 V-set domain-containing T-cell activation inhibitor 1 Human genes 0.000 claims 2
- 101150010086 VP24 gene Proteins 0.000 claims 2
- 101150026858 VP30 gene Proteins 0.000 claims 2
- 101150077651 VP35 gene Proteins 0.000 claims 2
- 101150036892 VP40 gene Proteins 0.000 claims 2
- 241001115400 Zaire ebolavirus Species 0.000 claims 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims 2
- 230000008350 antigen-specific antibody response Effects 0.000 claims 2
- 239000012634 fragment Substances 0.000 claims 2
- 230000004927 fusion Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000028327 secretion Effects 0.000 claims 2
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims 1
- 102100027207 CD27 antigen Human genes 0.000 claims 1
- 108010029697 CD40 Ligand Proteins 0.000 claims 1
- 101150013553 CD40 gene Proteins 0.000 claims 1
- 102100032937 CD40 ligand Human genes 0.000 claims 1
- 102100025221 CD70 antigen Human genes 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 102100037840 Dehydrogenase/reductase SDR family member 2, mitochondrial Human genes 0.000 claims 1
- 101150029662 E1 gene Proteins 0.000 claims 1
- 101150005585 E3 gene Proteins 0.000 claims 1
- 101150066038 E4 gene Proteins 0.000 claims 1
- 238000011510 Elispot assay Methods 0.000 claims 1
- 102100031351 Galectin-9 Human genes 0.000 claims 1
- 101100229077 Gallus gallus GAL9 gene Proteins 0.000 claims 1
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims 1
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 claims 1
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 claims 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 claims 1
- 101001068133 Homo sapiens Hepatitis A virus cellular receptor 2 Proteins 0.000 claims 1
- 101001019455 Homo sapiens ICOS ligand Proteins 0.000 claims 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 claims 1
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 claims 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 claims 1
- 101000914484 Homo sapiens T-lymphocyte activation antigen CD80 Proteins 0.000 claims 1
- 101000638251 Homo sapiens Tumor necrosis factor ligand superfamily member 9 Proteins 0.000 claims 1
- 101000851370 Homo sapiens Tumor necrosis factor receptor superfamily member 9 Proteins 0.000 claims 1
- 102100034980 ICOS ligand Human genes 0.000 claims 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 claims 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 claims 1
- 108090000174 Interleukin-10 Proteins 0.000 claims 1
- 102000013462 Interleukin-12 Human genes 0.000 claims 1
- 108010065805 Interleukin-12 Proteins 0.000 claims 1
- 108090000176 Interleukin-13 Proteins 0.000 claims 1
- 102000003810 Interleukin-18 Human genes 0.000 claims 1
- 108090000171 Interleukin-18 Proteins 0.000 claims 1
- 108010002386 Interleukin-3 Proteins 0.000 claims 1
- 102000000646 Interleukin-3 Human genes 0.000 claims 1
- 108010002616 Interleukin-5 Proteins 0.000 claims 1
- 108090001005 Interleukin-6 Proteins 0.000 claims 1
- 108090001007 Interleukin-8 Proteins 0.000 claims 1
- 102000004890 Interleukin-8 Human genes 0.000 claims 1
- 108010002335 Interleukin-9 Proteins 0.000 claims 1
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims 1
- 241000187479 Mycobacterium tuberculosis Species 0.000 claims 1
- 102000004473 OX40 Ligand Human genes 0.000 claims 1
- 108010042215 OX40 Ligand Proteins 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 claims 1
- 101710188053 Protein D Proteins 0.000 claims 1
- 101710132893 Resolvase Proteins 0.000 claims 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 claims 1
- 102100027222 T-lymphocyte activation antigen CD80 Human genes 0.000 claims 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 claims 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 claims 1
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 claims 1
- 102100028785 Tumor necrosis factor receptor superfamily member 14 Human genes 0.000 claims 1
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 claims 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 claims 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 claims 1
- 102100036856 Tumor necrosis factor receptor superfamily member 9 Human genes 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 229960005305 adenosine Drugs 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 239000002552 dosage form Substances 0.000 claims 1
- 238000003114 enzyme-linked immunosorbent spot assay Methods 0.000 claims 1
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000001939 inductive effect Effects 0.000 claims 1
- 238000012986 modification Methods 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562101968P | 2015-01-09 | 2015-01-09 | |
| US62/101,968 | 2015-01-09 | ||
| PCT/US2016/012482 WO2016112188A1 (en) | 2015-01-09 | 2016-01-07 | Methods and compositions for ebola virus vaccination |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018502922A JP2018502922A (ja) | 2018-02-01 |
| JP2018502922A5 true JP2018502922A5 (cg-RX-API-DMAC7.html) | 2019-02-14 |
Family
ID=56356425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017555422A Pending JP2018502922A (ja) | 2015-01-09 | 2016-01-07 | エボラウイルスワクチン接種のための方法および組成物 |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US10695417B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3256140B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018502922A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20170102002A (cg-RX-API-DMAC7.html) |
| CN (1) | CN107530383A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016205208A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2973109A1 (cg-RX-API-DMAC7.html) |
| ES (1) | ES2795833T3 (cg-RX-API-DMAC7.html) |
| WO (1) | WO2016112188A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009006479A2 (en) | 2007-07-02 | 2009-01-08 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
| US10695417B2 (en) | 2015-01-09 | 2020-06-30 | Etubics Corporation | Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein |
| AU2017297608B2 (en) * | 2016-07-15 | 2020-03-19 | Etubics Corporation | Compositions and methods for flavivirus vaccination |
| CA3030451C (en) * | 2016-07-15 | 2023-09-05 | Etubics Corporation | Compositions and methods for alphavirus vaccination |
| WO2018039640A1 (en) * | 2016-08-26 | 2018-03-01 | The Broad Institute, Inc. | Nucleic acid amplification assays for detection of pathogens |
| US20220339283A1 (en) * | 2019-09-10 | 2022-10-27 | The Penn State Research Foundation | Lipopolysaccharide molecules for enhancing immune responses |
| WO2021183717A1 (en) | 2020-03-11 | 2021-09-16 | Nantcell, Inc. | Proteinaceous therapeutics |
| US11857620B2 (en) | 2020-03-11 | 2024-01-02 | Immunitybio, Inc. | Method of inducing immunity against SARS-CoV-2 using spike (s) and nucleocapsid (N)-ETSD immunogens delivered by a replication-defective adenovirus |
| US12285480B2 (en) | 2020-03-11 | 2025-04-29 | Nantcell, Inc. | Method of inducing immunity against SARS-CoV-2 using spike and nucleocapsid-ETSD immunogens delivered by RNA and replication-defective adenoviruses |
| US20210284716A1 (en) * | 2020-03-11 | 2021-09-16 | Immunitybio, Inc. | ACE2-Fc Trap |
| KR20220154163A (ko) * | 2020-03-11 | 2022-11-21 | 이뮤니티바이오, 인크. | COVID-19의 치료 및 이를 위한 방법(Treatment of COVID-19 and Methods Therefor) |
| US20240327492A1 (en) | 2021-07-29 | 2024-10-03 | Nantcell, Inc. | Modified T Cell Receptors For The Prevention And Treatment Of Viral Infections And Cancer |
| EP4335870A1 (en) | 2022-09-06 | 2024-03-13 | NantCell, Inc. | Peptide therapeutics against sars-cov-2 spike protein |
| WO2024228950A1 (en) * | 2023-05-04 | 2024-11-07 | Immunitybio, Inc. | Adenoviral vector transduced apheresis product |
| WO2025238195A1 (en) * | 2024-05-16 | 2025-11-20 | Ferring International Center S.A. | Method for the purification of recombinant adenovirus vectors |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5549910A (en) | 1989-03-31 | 1996-08-27 | The Regents Of The University Of California | Preparation of liposome and lipid complex compositions |
| US5466468A (en) | 1990-04-03 | 1995-11-14 | Ciba-Geigy Corporation | Parenterally administrable liposome formulation comprising synthetic lipids |
| JP3218637B2 (ja) | 1990-07-26 | 2001-10-15 | 大正製薬株式会社 | 安定なリポソーム水懸濁液 |
| JP2958076B2 (ja) | 1990-08-27 | 1999-10-06 | 株式会社ビタミン研究所 | 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法 |
| US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
| US5830463A (en) | 1993-07-07 | 1998-11-03 | University Technology Corporation | Yeast-based delivery vehicles |
| US6045802A (en) | 1994-10-03 | 2000-04-04 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Enhanced immune response to an antigen by a composition of a recombinant virus expressing the antigen with a recombinant virus expressing an immunostimulatory molecule |
| US5795587A (en) | 1995-01-23 | 1998-08-18 | University Of Pittsburgh | Stable lipid-comprising drug delivery complexes and methods for their production |
| US5738868A (en) | 1995-07-18 | 1998-04-14 | Lipogenics Ltd. | Liposome compositions and kits therefor |
| US7118754B1 (en) | 1996-07-30 | 2006-10-10 | Transgene S.A. | Pharmaceutical composition for treating papillomavirus tumors and infection |
| US5994132A (en) | 1996-10-23 | 1999-11-30 | University Of Michigan | Adenovirus vectors |
| US6348450B1 (en) | 1997-08-13 | 2002-02-19 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom and uses thereof |
| DE69840524D1 (de) | 1997-08-13 | 2009-03-19 | Uab Research Foundation | Impfung durch topische verwendung genetischer vektoren |
| US6706693B1 (en) | 1997-08-13 | 2004-03-16 | The Uab Research Foundation | Vaccination by topical application of genetic vectors |
| US6716823B1 (en) | 1997-08-13 | 2004-04-06 | The Uab Research Foundation | Noninvasive genetic immunization, expression products therefrom, and uses thereof |
| ES2286530T3 (es) | 1997-10-10 | 2007-12-01 | The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services | Peptidos antagonistas del antigeno carcinoembrionario (cea). |
| EP1447414B1 (en) | 1997-10-10 | 2007-06-06 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES | Antagonist peptides of carcinoembryonic antigen (CEA) |
| US6969609B1 (en) | 1998-12-09 | 2005-11-29 | The United States Of America As Represented By The Department Of Health And Human Serivces | Recombinant vector expressing multiple costimulatory molecules and uses thereof |
| US6756038B1 (en) | 1997-10-10 | 2004-06-29 | The United States Of America As Represented By The Department Of Health And Human Services | Agonist and antagonist peptides of carcinoembryonic antigen (CEA) |
| US6413513B1 (en) | 1998-05-22 | 2002-07-02 | Entremed, Inc. | Compositions and methods for inhibiting endothelial cell proliferation and regulating angiogenesis using cancer markers |
| US6734172B2 (en) | 1998-11-18 | 2004-05-11 | Pacific Northwest Research Institute | Surface receptor antigen vaccines |
| CA2354024C (en) | 1998-12-09 | 2009-12-22 | Jeffrey Schlom | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
| US20040009936A1 (en) | 1999-05-03 | 2004-01-15 | Tang De-Chu C. | Vaccine and drug delivery by topical application of vectors and vector extracts |
| US7001995B1 (en) | 1999-08-25 | 2006-02-21 | Merck & Co., Inc. | Synthetic human papillomavirus genes |
| CA2388301C (en) | 1999-10-22 | 2011-01-04 | Aventis Pasteur Limited | Modified gp100 and uses thereof |
| WO2002008436A2 (en) | 2000-07-20 | 2002-01-31 | Genstar Therapeutics Corporation | Mini-adenoviral vector system for vaccination |
| US7083787B2 (en) | 2000-11-15 | 2006-08-01 | Globeimmune, Inc. | Yeast-dendritic cell vaccines and uses thereof |
| WO2003008537A2 (en) | 2001-04-06 | 2003-01-30 | Mannkind Corporation | Epitope sequences |
| US20040091995A1 (en) | 2001-06-15 | 2004-05-13 | Jeffrey Schlom | Recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses |
| US7410758B2 (en) | 2001-07-20 | 2008-08-12 | Board Of Regents, The University Of Texas System | Methods and compositions relating to HPV-associated pre-cancerous and cancerous growths, including CIN |
| US7786278B2 (en) | 2002-04-09 | 2010-08-31 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
| US8236776B2 (en) | 2002-04-09 | 2012-08-07 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
| EP1560597A4 (en) | 2002-10-29 | 2007-06-27 | Pharmacia Corp | DIFFERENTIALLY EXPRESSED GENES INVOLVED IN CANCER, POLYPEPTIDES CODED THEREWITH, AND METHODS OF USING GENES |
| CN1548537B (zh) | 2002-12-27 | 2010-05-05 | 深圳市源兴生物医药科技有限公司 | 疫苗制备方法和抗肿瘤疫苗 |
| US20070104685A1 (en) | 2003-05-05 | 2007-05-10 | Nicola La Monica | Synthetic gene encoding human carcinoembryonic antigen and uses thereof |
| US8207314B2 (en) | 2003-05-16 | 2012-06-26 | Sanofi Pasteur Limited | Tumor antigens for prevention and/or treatment of cancer |
| CA2532460C (en) | 2003-07-21 | 2012-04-24 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Synthetic gene encoding human epidermal growth factor 2/neu antigen and uses thereof |
| EP1687334B1 (en) | 2003-11-24 | 2014-01-08 | MicroVAX, LLC | Mucin antigen vaccine |
| EP1720905A2 (en) | 2003-12-11 | 2006-11-15 | Sidney Kimmel Cancer Center | Methods for generating immunity to antigen |
| DK1697399T3 (en) | 2003-12-12 | 2017-03-06 | Government Of The United States Of America As Repr By The Secr Of The Dept Of Health And Human Servi | Human cytotoxic t lymphocyte epitope and its agonist epitope from the non-variable number of muc-1 tandem repeat sequences |
| CA2555013C (en) | 2004-02-11 | 2013-10-15 | Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. | Carcinoembryonic antigen fusions and uses thereof |
| EP1742657B1 (en) * | 2004-04-28 | 2013-11-06 | The Trustees of The University of Pennsylvania | Immunization regimen with e4-deleted adenovirus prime and e1-deleted adenovirus boost |
| JP2008501360A (ja) | 2004-06-11 | 2008-01-24 | カソリック ユニバーシティー インダストリー アカデミー コオペレーション ファウンデーション | ＣＥＡ−特異的な細胞毒性Ｔ細胞を生成する組み換えアデノウイルスＡｄＶＣＥＡで形質導入された樹枝状細胞、及びこれを含むワクチン並びに薬剤学的組成物 |
| CN102614510A (zh) | 2004-10-18 | 2012-08-01 | 全球免疫股份有限公司 | 基于酵母的对慢性丙型肝炎感染的治疗 |
| US20100034840A1 (en) | 2005-07-11 | 2010-02-11 | David Apelian | Compositions and methods for eliciting an immune response to escape mutants of targeted therapies |
| EP1988919A4 (en) | 2006-02-02 | 2009-06-10 | Globeimmune Inc | VAKZINE ON YEAST BASE FOR TRIGGERING AN IMMUNE RESPONSE |
| BRPI0710242A2 (pt) | 2006-04-21 | 2011-08-09 | Transgene Sa | uso de uma composição |
| WO2009006479A2 (en) | 2007-07-02 | 2009-01-08 | Etubics Corporation | Methods and compositions for producing an adenovirus vector for use with multiple vaccinations |
| US8728489B2 (en) | 2008-09-19 | 2014-05-20 | Globeimmune, Inc. | Immunotherapy for chronic hepatitis C virus infection |
| WO2010065626A1 (en) | 2008-12-02 | 2010-06-10 | Globeimmune, Inc. | Genotyping tools, methods and kits |
| EP2419126B1 (en) | 2009-04-17 | 2018-01-10 | Globeimmune, Inc. | Combination immunotherapy compositions against cancer and methods |
| US20150182621A1 (en) | 2009-04-28 | 2015-07-02 | The Johns Hopkins University | Compositions and methods for enhancing antigen-specific immune responses |
| CA2774326C (en) | 2009-09-14 | 2023-11-07 | Donald Bellgrau | Modulation of yeast-based immunotherapy products and responses |
| WO2011115914A1 (en) | 2010-03-14 | 2011-09-22 | Globeimmune, Inc. | Pharmacogenomic and response-guided treatment of infectious disease using yeast-based immunotherapy |
| RU2578420C2 (ru) | 2010-05-10 | 2016-03-27 | Эсенд Байофармасьютикалз Пти Лтд | Иммуностимулирующие и вакцинные композиции |
| WO2012019127A2 (en) | 2010-08-05 | 2012-02-09 | The Regents Of The University Of Colorado | Combination yeast-based immunotherapy and arginine therapy for the treatment of myeloid-derived supressor cell-associated diseases |
| WO2012106490A1 (en) * | 2011-02-03 | 2012-08-09 | The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services | Multivalent vaccines for rabies virus and filoviruses |
| CN103476426B (zh) | 2011-02-12 | 2021-08-10 | 全球免疫股份有限公司 | 用于慢性乙型肝炎病毒感染的基于酵母的治疗剂 |
| SG10201605265TA (en) | 2011-06-14 | 2016-08-30 | Globeimmune Inc | Yeast-Based Compositions and Methods for the Treatment or Prevention of Hepatitis Delta Virus Infection |
| BR112014003477B1 (pt) | 2011-08-17 | 2021-11-03 | Globeimmune, Inc. | Composição imunoterapêutica de muc1 de levedura |
| SG10201606356YA (en) | 2012-02-02 | 2016-09-29 | Univ Texas | Adenoviruses expressing heterologous tumor-associated antigens |
| WO2014031178A1 (en) | 2012-08-24 | 2014-02-27 | Etubics Corporation | Replication defective adenovirus vector in vaccination |
| WO2014043518A1 (en) | 2012-09-14 | 2014-03-20 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use |
| TWI728239B (zh) | 2013-03-26 | 2021-05-21 | 美商環球免疫公司 | 治療或預防人類免疫缺乏病毒感染之組合物及方法 |
| WO2015031778A2 (en) | 2013-08-30 | 2015-03-05 | Globeimmune, Inc. | Compositions and methods for the treatment or prevention of tuberculosis |
| US10350275B2 (en) * | 2013-09-21 | 2019-07-16 | Advantagene, Inc. | Methods of cytotoxic gene therapy to treat tumors |
| EP3412304A3 (en) | 2013-10-23 | 2019-03-20 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Hla-a24 agonist epitopes of muc1-c oncoprotein and compositions and methods of use |
| EP4070818A3 (en) | 2014-01-06 | 2023-01-11 | The Trustees of the University of Pennsylvania | Pd1 and pdl1 antibodies and vaccine combinations and use of same for immunotherapy |
| US10434152B2 (en) | 2014-02-20 | 2019-10-08 | Wayne State University | HER2 antigenic polypeptide compositions, and methods for their use in treatment and prevention of carcinomas |
| WO2015157639A1 (en) | 2014-04-11 | 2015-10-15 | Globeimmune, Inc. | Yeast-based immunotherapy and type i interferon sensitivity |
| CN112494646A (zh) | 2014-06-30 | 2021-03-16 | 阿尔托生物科学有限公司 | 基于il-15的分子及其方法和用途 |
| EP3166646A4 (en) | 2014-07-07 | 2018-03-07 | Duke University | Vaccines against an oncogenic isoform of her2 (erbb2) and methods of using the same |
| EP3242940B1 (en) | 2015-01-09 | 2023-03-29 | Etubics Corporation | Methods and compositions for combination immunotherapy |
| US10695417B2 (en) | 2015-01-09 | 2020-06-30 | Etubics Corporation | Human adenovirus serotype 5 vectors containing E1 and E2B deletions encoding the ebola virus glycoprotein |
| US11149087B2 (en) | 2015-04-20 | 2021-10-19 | Etubics Corporation | Methods and compositions for combination immunotherapy |
-
2016
- 2016-01-07 US US15/542,003 patent/US10695417B2/en active Active
- 2016-01-07 WO PCT/US2016/012482 patent/WO2016112188A1/en not_active Ceased
- 2016-01-07 EP EP16735409.1A patent/EP3256140B1/en active Active
- 2016-01-07 AU AU2016205208A patent/AU2016205208A1/en not_active Abandoned
- 2016-01-07 ES ES16735409T patent/ES2795833T3/es active Active
- 2016-01-07 CA CA2973109A patent/CA2973109A1/en not_active Abandoned
- 2016-01-07 JP JP2017555422A patent/JP2018502922A/ja active Pending
- 2016-01-07 CN CN201680014847.2A patent/CN107530383A/zh active Pending
- 2016-01-07 KR KR1020177022208A patent/KR20170102002A/ko not_active Ceased
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502922A5 (cg-RX-API-DMAC7.html) | ||
| JP2018508567A5 (cg-RX-API-DMAC7.html) | ||
| JP2019176869A5 (cg-RX-API-DMAC7.html) | ||
| Swain et al. | Expanding roles for CD4+ T cells in immunity to viruses | |
| Bertram et al. | A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo | |
| Welsh et al. | Immunological memory to viral infections | |
| Bosio et al. | Ebola and Marburg virus-like particles activate human myeloid dendritic cells | |
| Condotta et al. | The immune battlefield: The impact of inflammatory cytokines on CD8+ T-cell immunity | |
| Marzi et al. | Ebola virus vaccines: an overview of current approaches | |
| Willoughby et al. | Differential impact of CD27 and 4-1BB costimulation on effector and memory CD8 T cell generation following peptide immunization | |
| JP2019508044A5 (cg-RX-API-DMAC7.html) | ||
| Gattoni et al. | Interferon-gamma: biologic functions and HCV therapy (type I/II)(1 of 2 parts). | |
| Buonaguro et al. | Immunogenomics and systems biology of vaccines | |
| JP2012515548A5 (cg-RX-API-DMAC7.html) | ||
| JP2020514378A5 (cg-RX-API-DMAC7.html) | ||
| Mahalingam et al. | The viral manipulation of the host cellular and immune environments to enhance propagation and survival: a focus on RNA viruses | |
| Wang et al. | Immune escape mechanisms of severe fever with thrombocytopenia syndrome virus | |
| CN112154204A (zh) | 基因工程化的细胞及应用 | |
| AU2016324479B2 (en) | Immunogenic antigen identification from a pathogen and correlation to clinical efficacy | |
| Tang et al. | CD28 family of receptors on T cells in chronic HBV infection: expression characteristics, clinical significance and correlations with PD-1 blockade | |
| van der Burg et al. | Immunotherapy for persistent viral infections and associated disease | |
| Garrod et al. | DNA vaccines encoding membrane‐bound or secreted forms of heat shock protein 70 exhibit improved potency | |
| Kale et al. | An overview of current accomplishments and gaps of COVID-19 vaccine platforms and considerations for next generation vaccines | |
| Sanchez et al. | An alternative signal 3: CD8+ T cell memory independent of IL-12 and type I IFN is dependent on CD27/OX40 signaling | |
| Buonaguro et al. | Systems biology applied to vaccine and immunotherapy development |